FEMCON FE
Clinical safety rating
cautionComprehensive clinical and safety monograph for FEMCON FE (FEMCON FE).
Combination oral contraceptive containing norethindrone and ethinyl estradiol. Inhibits ovulation via suppression of gonadotropins (FSH, LH); increases cervical mucus viscosity, impairing sperm penetration; alters endometrial receptivity.
| Metabolism | Norethindrone is metabolized primarily via reduction and sulfate conjugation; ethinyl estradiol is metabolized via CYP3A4 and glucuronidation. |
| Excretion | Renal excretion accounts for approximately 40-60% of the dose as metabolites; fecal excretion is about 20-30% via bile. Unchanged drug excretion is minimal. |
| Half-life | The terminal elimination half-life of ethinyl estradiol is 13-18 hours; for norethindrone, it is 7-12 hours. Both allow once-daily dosing for contraceptive efficacy. |
| Protein binding | Ethinyl estradiol is approximately 98% bound to albumin and sex hormone-binding globulin (SHBG); norethindrone is about 80% bound to albumin and SHBG. |
| Volume of Distribution | Ethinyl estradiol: 2.3-4.1 L/kg; norethindrone: 3.6-4.5 L/kg. Indicates extensive tissue distribution, including reproductive tissues. |
| Bioavailability | Oral bioavailability: ethinyl estradiol ~40-45% (due to first-pass metabolism); norethindrone ~60-80%. Ferrous fumarate (iron supplement) has low bioavailability but is not relevant for contraception. |
| Onset of Action | Contraceptive effect begins after 7 consecutive days of active pills when taken correctly. Ovulation suppression may occur earlier. |
| Duration of Action | Duration of contraceptive effect lasts throughout the 21-day active pill cycle; after last active pill, effects wane over 5-7 days, leading to withdrawal bleed. Missed pills risk ovulation. |
| Molecular Weight | Norethindrone: 298.42 Da; Ethinyl Estradiol: 296.40 Da |
One tablet (norethindrone 0.5 mg + ethinyl estradiol 35 mcg) orally once daily for 28 days.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment due to potential estrogen accumulation. |
| Liver impairment | Contraindicated in severe hepatic disease (Child-Pugh class C). Use with caution in Child-Pugh class A or B; consider alternative contraception. |
| Pediatric use | Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily). |
| Geriatric use | Not indicated for use in postmenopausal women. No dose adjustment required for healthy elderly; consider risks of thromboembolism and metabolic effects. |
| 1st trimester | Contraindicated; risk of fetal harm including orofacial clefts, heart defects, and neural tube defects. |
| 2nd trimester | Contraindicated; continued risk of fetal harm including genitourinary abnormalities and hormonal effects. |
| 3rd trimester | Contraindicated; risk of fetal harm such as feminization of male fetuses and hormonal imbalances. |
Clinical note
Comprehensive clinical and safety monograph for FEMCON FE (FEMCON FE).
| Placental transfer | Both norethindrone and ethinyl estradiol cross the placenta; demonstrated in animal and human studies. |
| Breastfeeding | Contraindicated in breastfeeding; estrogen and progestin can reduce milk production and composition. Norethindrone and ethinyl estradiol are excreted in breast milk in small amounts; potential adverse effects in nursing infant. |
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | FDA Pregnancy Category X. Contraindicated in pregnancy due to known teratogenicity. First trimester exposure is associated with cardiovascular defects, neural tube defects, and limb reduction defects. Second and third trimester exposure carries risks of fetal genital abnormalities (e.g., virilization of female fetuses from progestin component). |
| Fetal Monitoring | Avoid pregnancy; conduct pregnancy test before initiation. Monitor for signs of pregnancy; if pregnancy occurs, discontinue immediately and counsel regarding risks. No fetal monitoring required if contraindication is respected. |
| Fertility Effects | Designed to prevent ovulation; after discontinuation, fertility typically returns to baseline within 1-3 cycles. No lasting negative impact on fertility. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (>35 years) and number of cigarettes smoked. Women who use combination oral contraceptives should be strongly advised not to smoke.
| Serious Effects |
Known or suspected pregnancyBreast cancer (current or history)Hepatic adenoma or carcinomaUndiagnosed abnormal uterine bleedingHypersensitivity to any componentThromboembolic disorders or historyCerebrovascular diseaseCoronary artery diseaseActive liver disease (e.g., hepatitis, cirrhosis)
| Precautions | Thrombotic disorders (venous thromboembolism, stroke, MI), Cardiovascular disease (especially in smokers >35 years), Hepatic neoplasia, Gallbladder disease, Hypertension, Carbohydrate/lipid effects, Headache/migraine, Uterine bleeding irregularities, Ocular effects (retinal thrombosis), Depression |
| Food/Dietary | No significant food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically relevant. Avoid excessive alcohol as it may increase liver enzymes and alter hormone metabolism. |
| Clinical Pearls | Monitor for thromboembolic events. Counsel on the importance of consistent daily dosing. Advise that withdrawal bleeding may be absent or lighter. Contraindicated in breastfeeding within 21 days postpartum due to estrogen effects. Use with caution in migraine with aura. |
| Patient Advice | Take one tablet daily at the same time each day. · If you miss a pill, follow the instructions in the package insert or ask your healthcare provider. · Femcon Fe may cause nausea; taking with food can reduce this. · Bleeding may be irregular initially; consistent use improves cycle control. · This medication does not protect against HIV or other STDs. |
Loading safety data…